Zobrazeno 1 - 10 of 73 pro vyhledávání: '"Jf, Prost"'
1
Comparison of the effects of intravenous almitrine and positive end-expiratory pressure on pulmonary gas exchange in adult respiratory distress syndrome
Autor: JF Prost, P Desche, F Jardin, A Margairaz
Publikováno v: European Respiratory Journal. 4:683-687
The effects of almitrine on pulmonary gas exchange and haemodynamics were compared to those of positive end-expiratory pressure (PEEP) in 10 patients with a severe adult respiratory distress syndrome (ARDS) who required continuous mechanical ventilat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::312fb7d30ee91ba6e7b3c738c919f425
https://doi.org/10.1183/09031936.93.04060683
Zobrazit plný text záznamu
2
Inactivation of isocitrate dehydrogenase kinase/phosphatase by 5'-[p-(fluorosulfonyl)benzoyl]adenosine is not due to the labeling of the invariant lysine residue found in the protein kinase family
Autor: Oudot, C., Jm Jault, Jaquinod, M., Didier NEGRE, Jf Prost, Aj Cozzone, Jc Cortay
Publikováno v: European Journal of Biochemistry
European Journal of Biochemistry, Wiley, 1998, 258, pp.579-585
HAL
International audience; The ATPase activity of Escherichia coli isocitrate dehydrogenase kinase/phosphatase was rapidly lost after prior incubation with the ATP analogue 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSBA). This inactivation was prevented
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ebba1ae2e161f2cd0b68302ef8f8209f
https://hal.archives-ouvertes.fr/hal-00313212
Zobrazit plný text záznamu
3
Effects of the bradykinin B2 receptor antagonist S 16118 (p-guanidobenzoyl-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) in different in vivo animal models of inflammation
Autor: Félétou M, Lonchampt M, Robineau P, Jamonneau I, Thurieau C, Jl, Fauchère, Villa P, Pietro Ghezzi, Jf, Prost, Canet E
Publikováno v: Europe PubMed Central
The effects of S 16118 (p-guanidobenzoyl-[Hyp3,Thi5,D-Tic7, Oic8]bradykinin (BK)], a new, potent and long-acting BK B2 antagonist, were tested in some in vivo models of inflammation. In rats, S 16118 (0.1 and 1 mg/kg) given i.v. or s.c. delayed the e
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::de145fe7d89c2f42a4b0a9d930e8d2b3
https://pubmed.ncbi.nlm.nih.gov/7791078
Zobrazit plný text záznamu
4
Akademický článek
Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.
Autor: Prat M; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France., Salon M; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, UPS, 31100 Toulouse, France., Allain T; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France., Dubreuil O; GamaMabs Pharma, 31106 Toulouse, France., Noël G; Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium., Preisser L; Univ Angers, Université de Nantes, CHU Angers, Inserm, CRCINA, SFR ICAT, 49000 Angers, France., Jean B; GamaMabs Pharma, 31106 Toulouse, France., Cassard L; Laboratory of Immunomonitoring in Oncology, Gustave Roussy, 94905 Villejuif, France., Lemée F; GamaMabs Pharma, 31106 Toulouse, France., Tabah-Fish I; GamaMabs Pharma, 31106 Toulouse, France., Pipy B; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, UPS, 31100 Toulouse, France., Jeannin P; Univ Angers, Université de Nantes, CHU Angers, Inserm, CRCINA, SFR ICAT, 49000 Angers, France., Prost JF; GamaMabs Pharma, 31106 Toulouse, France., Barret JM; GamaMabs Pharma, 31106 Toulouse, France., Coste A; UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France.; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, UPS, 31100 Toulouse, France.
Publikováno v: Cancers [Cancers (Basel)] 2021 Apr 13; Vol. 13 (8). Date of Electronic Publication: 2021 Apr 13.
Zobrazit plný text záznamu
5
Akademický článek
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer.
Autor: Barret JM; GamaMabs Pharma, Centre Pierre Potier, F-31100 Toulouse, France., Nicolas A; Department of Diagnostic and Theranostic Medicine, Platform of Experimental Pathology, Institut Curie, PSL Research University, F-75005 Paris, France., Jarry A; Université de Nantes, Inserm U1232, CRCINA, F-44000 Nantes, France., Dubreuil O; GamaMabs Pharma, Centre Pierre Potier, F-31100 Toulouse, France., Meseure D; Department of Diagnostic and Theranostic Medicine, Platform of Experimental Pathology, Institut Curie, PSL Research University, F-75005 Paris, France., Passat T; Université de Nantes, Inserm U1232, CRCINA, F-44000 Nantes, France., Perrial E; Cancer Research Centre de Lyon, Inserm 1052, CNRS 5286, F-69008 Lyon, France., Deleine C; Université de Nantes, Inserm U1232, CRCINA, F-44000 Nantes, France., Champenois G; Department of Diagnostic and Theranostic Medicine, Platform of Experimental Pathology, Institut Curie, PSL Research University, F-75005 Paris, France., Gaillard S; GamaMabs Pharma, Centre Pierre Potier, F-31100 Toulouse, France., Duchalais E; Service de Chirurgie Digestive et Endocrinienne, Centre Hospitalier Universitaire Hôtel Dieu, F-44000 Nantes, France., Ray-Coquard I; Laboratory RESHAPE U1290, Léon Bérard Cancer Centre, F-69008 Lyon, France., Lahmar M; GamaMabs Pharma, Centre Pierre Potier, F-31100 Toulouse, France., Dumontet C; Cancer Research Centre de Lyon, Inserm 1052, CNRS 5286, F-69008 Lyon, France., Bennouna J; Service Oncologie Digestive, Institut des Maladies de l'Appareil Digestif, Centre Hospitalier Universitaire Hôtel Dieu, F-44000 Nantes, France., Bossard C; Service Anatomie Pathologique, Centre Hospitalier Universitaire Hôtel Dieu, Inserm 1232, CRCINA, F-44000 Nantes, France., Roman-Roman S; Translational Research Department, Institut Curie, Research University, F-75005 Paris, France., Prost JF; GamaMabs Pharma, Centre Pierre Potier, F-31100 Toulouse, France.
Publikováno v: Biology [Biology (Basel)] 2021 Apr 07; Vol. 10 (4). Date of Electronic Publication: 2021 Apr 07.
Zobrazit plný text záznamu
6
Akademický článek
Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
Autor: Georges JL; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Gilles F; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Cochet H; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Bertrand A; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., De Tournemire M; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Monguillon V; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Pasqualini M; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Prevot A; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Roger G; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Saba J; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Soltani J; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Koukabi-Fradelizi M; Emergency Department, Centre Hospitalier de Versailles, Le Chesnay, France., Beressi JP; Department of Diabetology, Centre Hospitalier de Versailles, Le Chesnay, France., Laureana C; Department of Medical Information, Centre Hospitalier de Versailles, Le Chesnay, France., Prost JF; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France., Livarek B; Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France.
Publikováno v: PloS one [PLoS One] 2020 Dec 21; Vol. 15 (12), pp. e0244349. Date of Electronic Publication: 2020 Dec 21 (Print Publication: 2020).
Zobrazit plný text záznamu
7
Akademický článek
Circulating CD14 high CD16 low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression.
Autor: Prat M; UMR152 Pharmadev, Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France.; UMR152 Pharmadev, IRD, Toulouse, France., Le Naour A; UMR152 Pharmadev, Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France.; UMR152 Pharmadev, IRD, Toulouse, France.; UMR1037, CRCT, Toulouse, Midi-Pyrénées, France.; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Coulson K; UMR152 Pharmadev, Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France.; UMR152 Pharmadev, IRD, Toulouse, France., Lemée F; Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France., Leray H; UMR1037, CRCT, Toulouse, Midi-Pyrénées, France.; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Jacquemin G; UMR152 Pharmadev, Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France.; UMR152 Pharmadev, IRD, Toulouse, France., Rahabi MC; UMR152 Pharmadev, Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France.; UMR152 Pharmadev, IRD, Toulouse, France., Lemaitre L; UMR1037, CRCT, Toulouse, Midi-Pyrénées, France.; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Authier H; UMR152 Pharmadev, Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France.; UMR152 Pharmadev, IRD, Toulouse, France., Ferron G; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Barret JM; Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France., Martinez A; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Ayyoub M; UMR1037, CRCT, Toulouse, Midi-Pyrénées, France., Delord JP; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Gladieff L; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Tabah-Fisch I; Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France., Prost JF; Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France., Couderc B; UMR1037, CRCT, Toulouse, Midi-Pyrénées, France.; Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France., Coste A; UMR152 Pharmadev, Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France agnes.coste@univ-tlse3.fr.; UMR152 Pharmadev, IRD, Toulouse, France.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Jun; Vol. 8 (1).
Zobrazit plný text záznamu
8
Akademický článek
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.
Autor: Ho-Pun-Cheung A; ICM, Institut régional du Cancer de Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Bazin H; CisBio SA, Codolet, France., Boissière-Michot F; ICM, Institut régional du Cancer de Montpellier, Montpellier, France., Mollevi C; ICM, Institut régional du Cancer de Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Simony-Lafontaine J; ICM, Institut régional du Cancer de Montpellier, Montpellier, France., Landas E; CisBio SA, Codolet, France., Bleuse JP; ICM, Institut régional du Cancer de Montpellier, Montpellier, France., Chardès T; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Prost JF; GamaMabs Pharma SA, Centre Pierre Potier, Toulouse, France., Pèlegrin A; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Jacot W; ICM, Institut régional du Cancer de Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Mathis G; CisBio SA, Codolet, France., Lopez-Crapez E; ICM, Institut régional du Cancer de Montpellier, Montpellier, France. evelyne.crapez@icm.unicancer.fr.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France. evelyne.crapez@icm.unicancer.fr.
Publikováno v: British journal of cancer [Br J Cancer] 2020 Feb; Vol. 122 (3), pp. 397-404. Date of Electronic Publication: 2019 Dec 03.
Zobrazit plný text záznamu
9
Akademický článek
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
Autor: Le Clorennec C; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France.; Present Address: UCSD School of Medicine, Moores Cancer Center, La Jolla, CA, 92093-0815, USA., Lazrek Y; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France.; Present Address: Institut Pasteur de Guyane, F- 97306, Cayenne, France., Dubreuil O; GamaMabs Pharma SA, Centre Pierre Potier, F-31106, Toulouse, France., Sampaio C; Laboratoire d'Immunologie et d'Immunothérapie des Cancers, EA7269, Université Bourgogne Franche-Comté, F-21000, Dijon, France., Larbouret C; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France., Lanotte R; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France., Poul MA; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France., Barret JM; GamaMabs Pharma SA, Centre Pierre Potier, F-31106, Toulouse, France., Prost JF; GamaMabs Pharma SA, Centre Pierre Potier, F-31106, Toulouse, France., Pèlegrin A; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France., Chardès T; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France. thierry.chardes@inserm.fr.; Centre National de la Recherche Scientifique (CNRS), Paris, France. thierry.chardes@inserm.fr.
Publikováno v: Cell communication and signaling : CCS [Cell Commun Signal] 2019 Aug 23; Vol. 17 (1), pp. 106. Date of Electronic Publication: 2019 Aug 23.
Zobrazit plný text záznamu
10
Akademický článek
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.
Autor: Bougherara H; Inserm, U1016, Institut Cochin, Paris, France.; Cnrs, UMR8104, Paris, France.; Université Paris Descartes, Sorbonne Paris Cité, Paris, France., Némati F; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Nicolas A; Department of Tumor Biology, Institut Curie, Paris, France., Massonnet G; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Pugnière M; INSERM U896, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France., Ngô C; Department of Gynaecological and Oncological Surgery, Hôpital Européen Georges Pompidou, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France., Le Frère-Belda MA; Department of Pathology, Hôpital Européen Georges Pompidou, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France., Leary A; Gustave Roussy Hospital, Inserm U981, Villejuif, France., Alexandre J; Inserm, U1016, Institut Cochin, Paris, France.; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.; Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Meseure D; Department of Tumor Biology, Institut Curie, Paris, France., Barret JM; GammaMabs Pharma, Centre Pierre Potier, Toulouse, France., Navarro-Teulon I; INSERM U896, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France., Pèlegrin A; INSERM U896, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France., Roman-Roman S; Department of Translational Research, Institut Curie, PSL University, Paris, France., Prost JF; GammaMabs Pharma, Centre Pierre Potier, Toulouse, France., Donnadieu E; Inserm, U1016, Institut Cochin, Paris, France.; Cnrs, UMR8104, Paris, France.; Université Paris Descartes, Sorbonne Paris Cité, Paris, France., Decaudin D; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.; Department of Medical Oncology, Institut Curie, Paris, France.
Publikováno v: Oncotarget [Oncotarget] 2017 Oct 07; Vol. 8 (59), pp. 99950-99965. Date of Electronic Publication: 2017 Oct 07 (Print Publication: 2017).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje